MedTrace Logo

Uric Acid in Essential Hypertension in Children

NCT00288184 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-09-14

No results posted yet for this study

Summary

The study is a randomized, double-blinded, placebo controlled, crossover trial of allopurinol for the treatment of children with newly diagnosed essential hypertension.

Conditions

  • Essential Hypertension

Interventions

DRUG

Allopurinol

Allopurinol adminsitered one 200mg capsule by mouth twice daily. Placebo capsule once daily during crossover

DRUG

Placebo

Sponsors & Collaborators

  • Baylor University

    collaborator OTHER

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    lead NIH

Principal Investigators

  • Daniel I. Feig, MD, PhD · Baylor College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
12 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Primary Completion
2007-03-31
Completion
2007-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00288184 on ClinicalTrials.gov